

HIPRA inaugurates its new Campus in Girona, one of Europe's leading biotechnology hubs

It foresees a capital investment of more than 500 million euros.

The new HIPRA Campus, spanning 114,000 m², will house R&D units, manufacturing, and the company's strategic development, generating more than 1,000 jobs once completed.

The inauguration was attended by Salvador Illa, President of the Generalitat of Catalonia, and Jordi Hereu, Minister of Industry and Tourism of the Government of Spain.

Girona, September 18, 2025 – The biopharmaceutical company HIPRA has officially inaugurated its new HIPRA Campus in Aiguaviva (Girona), envisioned as one of Europe's main biotechnology hubs. The event was presided over by Salvador Illa, President of the Generalitat of Catalonia, and attended by Jordi Hereu, Minister of Industry and Tourism of the Government of Spain, along with other distinguished authorities.

The Campus is **the strategic cornerstone on which HIPRA's growth and expansion will rest in the coming years**. It has been conceived to be much more than an infrastructure: through this Campus, HIPRA aims to consolidate its position as a **benchmark in the biotechnology sector**, ranking among the leading companies in Europe and projecting its influence globally. This space symbolizes HIPRA's vision for the future and reinforces its commitment to developing innovative solutions that address major global health challenges.

Salvador Illa, President of the Generalitat de Catalunya, emphasized that "infrastructures like the HIPRA Campus we have inaugurated today are crucial because they generate economic, social, and, above all, health prosperity. Investing in research will allow us to accelerate science and contribute to the most important thing we have: health.

We must believe that we are capable of generating impact in Europe and worldwide. Government, companies, institutions, research centers, and universities must work with determination to create impact," said Illa.

The Campus extends HIPRA's headquarters in Amer (Girona) and strengthens its productive, scientific, and technological capacity, aligned with a sustainable and international growth strategy. With an estimated **capital investment of over 500 million euros and a surface of**

114,000 m² of new industrial land (doubling the area of its headquarters), the HIPRA Campus seeks to establish itself as an international centre of excellence in the research and development of high-impact biotechnological solutions for global health. **Phase 1 of the project, already completed, comprises 28,000 m² of built space**, distributed among production, corporate, and R&D buildings. Of this, **7,500 m² are specifically dedicated to R&D in animal and human health, tripling the company's current capacity in this field.**

Jordi Hereu, Minister of Industry and Tourism of the Government of Spain, expressed that “we are at a time when it is necessary to strengthen Europe, for economic, social, and health reasons. Europe's future strategies will require facilities and capacities like this Campus, which stands as a biotechnological resilience structure for the future. In addition, HIPRA is leading cutting-edge projects such as EU-FAB and Speedcell, focused on achieving the goal of strategic autonomy, which are essential for global public health.”

The new HIPRA Campus also represents **a magnet for scientific, technological, and industrial talent**, which is essential to driving the innovation that defines HIPRA's leadership in the biotechnology sector. HIPRA aims to attract **international talent, consolidate local and national expertise**, create opportunities for both **young professionals and senior experts, and continue growing in diversity.**

“For us, the HIPRA Campus is not just a state-of-the-art facility; it is an ecosystem where science, technology, strategy, and sustainability converge. Our goal is clear: to make the HIPRA Campus one of the leading biotechnology hubs in Europe. We are investing decisively to lead the development of innovative biotechnological solutions in both human and animal health. In addition, we have a fully integrated technological capacity and value chain, which allows us to act with agility and autonomy, something key to reinforcing health resilience in Europe,” highlighted David Nogareda, President and CEO of HIPRA, during the event.

A hub of innovation with global impact

The HIPRA Campus, which already employs more than 400 professionals, will reach **1,000 direct jobs and more than 2,000 indirect jobs once completed**. These professionals will add to **a workforce of over 2,700 employees currently based in the province of Girona and in its 40**

subsidiaries worldwide. Designed as a collaborative and sustainable working environment, the Campus includes laboratories and production plants equipped with the latest technologies, green spaces, and employee services.

“The development of this biotechnology campus demonstrates HIPRA’s firm commitment to **continuing as a global health benchmark** and to advancing the development of groundbreaking new vaccines. With a portfolio of **108 vaccines, 35 innovative vaccine projects underway, and a team of experts working on more than 300 pathogens affecting humans and animals**, the company positions itself as **a key ally for Europe’s strategic health autonomy**. This strength, along with a fully integrated value chain—from research and development to manufacturing and distribution, allows HIPRA to respond quickly and independently to health crises, reinforcing the One Health approach that guides its commitment to prevention and improved global health,” stated Laura Ferrer, Director of R&D in the Human Health Division.

Highlights of the **new facilities** include:

- An R&D building with 7,500 m² dedicated to research in animal and human health, tripling the company’s current capacity.
- The Business and Technology building, with four floors and 8,000 m², dedicated to manufacturing medical devices and housing three levels of offices, a data center, and meeting rooms.
- Bacterial Cultures Unit 6, with 5,570 m² and BSL2+ biosafety level, featuring a complete park of fermenters and bioreactors of up to 2,000 L, centrifuges, and filtration systems for the production of antigens and recombinant proteins derived from bacteria, mycoplasmas, and yeasts.
- Cell Culture Platform Unit 1, with 4,285 m², currently in the equipment phase, which will complete the cycle by producing antigens, recombinant proteins, and monoclonal antibodies for human health.
- Together, Bacterial Cultures Unit 6 and Cell Culture Platform Unit 1 account for more than 9,000 m² dedicated to the manufacture of biological products.

- Auxiliary buildings for services, energy, and water treatment, all designed under criteria of efficiency, scalability, and sustainability.

A sustainable Campus

Sustainability has been a cornerstone in the design and construction of the new HIPRA Campus. The facilities incorporate **advanced energy and water efficiency systems**, such as a **centralized District Heating and Cooling network and rainwater recovery**, significantly reducing resource consumption, CO₂ emissions, and environmental footprint. This commitment reflects HIPRA's intention to promote a responsible growth model aligned with the **Sustainable Development Goals** and its responsibility toward global health and the environment.

About HIPRA

HIPRA is a biopharmaceutical company focused on prevention for animal and human health (One Health), offering a wide range of highly innovative vaccines and advanced diagnostic services. With its claim **“Building immunity for a healthier world”**, HIPRA reaffirms its commitment to providing solutions that improve global health. It has a strong international presence with **40 subsidiaries, 3 R&D centres, and 6 manufacturing centres** strategically located in Europe (Spain) and America (Brazil). In addition, its extensive international distribution network maintains commercial channels in nearly 100 more countries, covering all five continents.

Research and development are the core of its expertise. HIPRA **invests more than 15% of its annual revenue in R&D** activities focused on applying the latest scientific advances to develop top-quality innovative vaccines.

HIPRA has a portfolio of vaccines based on diverse technological platforms. Its R&D teams work with a wide variety of technologies and biological modalities.

To enhance its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

Contactos de prensa

Irene Calle – icalle@harmon.es – M. 609 873 052

José María Nieto – jnieto@harmon.es – M. 689 186 062